Department of Radiology, Radboud University Nijmegen Medical Centre, Geert Grooteplein Zuid 10, P.O. Box 9101 (766), 6500 HB, Nijmegen, the Netherlands.
Curr Urol Rep. 2013 Jun;14(3):209-13. doi: 10.1007/s11934-013-0323-z.
In-bore magnetic resonance-guided biopsy (MRGB) has been increasingly used in clinical practice to detect prostate cancer (PCa). This review summarizes the current clinical results of this biopsy method. A systematic literature search was performed in the PubMed and Embase databases. Of 2,035 identified records, 49 required full review. In all, ten unique studies reporting clinical results of MRGB could be included. Reported PCa detection rates ranged from 8 to 59 % (median 42 %). The majority of tumors detected by MRGB were clinically significant (81-93 %). Most frequent complications of MRGB are transient hematuria (1-24 %) and short-term perirectal bleeding (11-17 %). Major complications are rare. Based on the reviewed literature, MRGB can be regarded an accurate and safe diagnostic tool to detect clinically significant PCa. However, as general availability is limited, this procedure should be reserved for specific patients. Appropriate indications will have to be determined.
在体磁共振引导活检（MRGB）已越来越多地用于临床实践中，以检测前列腺癌（PCa）。本文综述了该活检方法的当前临床结果。在 PubMed 和 Embase 数据库中进行了系统的文献检索。在 2035 条鉴定记录中，有 49 条需要进行全面审查。共有 10 项独特的研究报告了 MRGB 的临床结果，可以纳入本研究。报告的 PCa 检出率为 8-59%（中位数为 42%）。MRGB 检测到的大多数肿瘤具有临床意义（81-93%）。MRGB 最常见的并发症是短暂性血尿（1-24%）和短期直肠周围出血（11-17%）。严重并发症罕见。根据已审查的文献，MRGB 可以被视为一种准确且安全的诊断工具，用于检测具有临床意义的 PCa。然而，由于普遍可用性有限，该程序应保留给特定患者。需要确定适当的适应证。
